| abstract |
The present invention provides a method for minimizing the bone loss effect of a compound of formula IIn n or a pharmaceutically acceptable salt thereof, wherein said formula II compound is administered to a mammal in need of treatment, comprising concurrently or sequentially administering to said mammal an effective amount of a compound of formula In n wherein n each R 1 is independently -H, -OH, -O(C 1 -C 4 alkyl), -OCOC 6 H 5 , -OCO(C 1 -C 6 alkyl), or -OSO 2 (C 4 -C 6 alkyl); and n R 2 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; nor a pharmaceutically acceptable salt thereof. n Also provided is a method for minimizing bone loss induced by the administration of a formula II compound comprising concurrently or sequentially administering a bone anabolic agent. Pharmaceutical compositions are also provided. |